Structure-activity relationship in the 3-iodo-4-phenoxypyridinone (IOPY) series: The nature of the C-3 substituent on anti-HIV activity

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 3, 2007, Pages 712-716

  Benjahad, Abdellah ^a   Oumouch, Said ^a   Guillemont, Jerôme ^b   Pasquier, Elisabeth ^b   Mabire, Dominique ^b   Andries, Koen ^c   Nguyen, Chi Hung ^a   Grierson, David S ^a  

^a CNRS   (France)

^b JOHNSON AND JOHNSON   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Anti HIV; IOPY; NNRTI; Pyridinone

Indexed keywords

3 IODO 4 PHENOXYPYRIDINONE; ASPARAGINE; CYSTEINE; ISOLEUCINE; LEUCINE; LYSINE; PYRIDONE DERIVATIVE; TYROSINE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTANT; NONHUMAN; VIRUS STRAIN; WILD TYPE;

ANTI-HIV AGENTS; CELL LINE; HIV-1; HUMANS; INDICATORS AND REAGENTS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR CONFORMATION; PYRIDONES; STRUCTURE-ACTIVITY RELATIONSHIP;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33846378472     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.10.082     Document Type: Article

References (15)

1. Benjahad A., Guillemont J., Andries K., Nguyen C.H., and Grierson D.S. Bioorg. Med. Chem. Lett. 13 (2003) 4309
2. Dolle V., Fan E., Nguyen C.H., Aubertin A.-M., Kirn A., Andreola M.L., Jamieson G., Tarrago-Litvak L., and Bisagni E. J. Med. Chem. 38 (1995) 4679
3. 3) δ 13.45 (1H, br s), 6.68 (1H, s), 6.47 (2H, s), 2.44 (3H, s), 2.35 (2H, q, J = 7.3 Hz), 2.26 (6H, s), 0.99 (3H, t, J = 7.3 Hz) MS (ES): m/z 334.1 and 336.1 (M-H).
4. 3) δ 12.28 (1H, br s), 6.40-6.70 (4H, m), 5.32 (1H, dd, J = 10.3 and 4.4 Hz), 3.73 (3H, s),. 2.39 (3H, s), 2.20-2.35 (8H, m), 0.97 (3H, t, J = 7.4 Hz) MS (ES): m/z 282.2 (M-H).
5. Dickens M.J., Gilday J.P., Mowlem T.J., and Widdowson D.A. Tetrahedron 47 (1991) 8621
6. Yang Z., Lorenz J.C., and Shi Y. Tetrahedron Lett. 39 (1998) 8621
7. 3) δ 13.33 (1H, br s), 7.25 (1H, s), 6.44 (2H, s), 2.42 (3H, s), 2.34 (3H, s), 2.31 (2H, q, J = 7.3 Hz), 2.25 (6H, s), 0.98 (3H, t, J = 7.3 Hz) MS (ES): m/z 302.1 (M-H).
8. Kobayashi K., Koyama E., Namatame K., Kitaura T., Kono C., Goto M., Obinata T., and Furukawa N. J. Org. Chem. 64 (1999) 3190
9. 3): C, 71.06; H, 7.37; N, 4.87. Found: C, 70.76; H, 7.42; N,4.82.
10. Mitsunobu O. Synthesis (1981) 1
11. Castro B.R. Org. React. 29 (1983) 1
12. Chen Q.-Y., and Wu S.-W. J. Chem. Soc., Chem. Commun. (1989) 705
13. 50, nM) to achieve 50% protection of MT-4 cells from HIV-1 cytopathicity as determined by the MTT method:. Pauwels R., Balzarini J., Baba M., Snoek R., Schols D., Herdewijn P., Desmyter J., and De Clercq E. J. Virol. Methods 20 (1988) 309 Unless noted otherwise, the LAI strain of HIV-1 was the infecting virus. Other infecting mutant (in the reverse transcriptase) strains of virus are characterized in the tables by the mutated amino acid position and the one letter codes. For instance, 181C refers to replacement of tyrosine at position 181 with cysteine. All determinations are average values for three or more tests
14. Himmel D.M., Das K., Clark Jr. A.D., Hughes S.H., Benjahad A., Oumouch S., Guillemont J., Coupa S., Poncelet A., Csoka I., Meyer C., Andries K., Nguyen C.H., Grierson D.S., and Arnold E. J. Med. Chem. 48 (2005) 7582
15. Hopkins A.L., Ren J., Tanaka H., Baba M., Okamato M., Stuart D.I., and Stammers D.K. J. Med. Chem. 42 (1999) 4500